SystImmune, Inc. Announces the Presentation of Breast Cancer Clinical Trial Results at the 2023 San Antonio Breast Cancer Conference and US Clinical Trial Developments
SystImmune, Inc (SystImmune), a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) authorized the company to proceed with the planned clinical study of the HER2-specific HIRE platform ADC, BL-M07D1, in the Investigational New Drug (IND) application…
Synthego Bridges Critical Preclinical Gap to Accelerate CRISPR-based Cell and Gene Therapies
Synthego, a leading provider of genome engineering solutions, today announced the launch of its IND-enabling (INDe) gRNAs, a transformative product offering that revolutionizes the CRISPR-based cell and gene therapy preclinical pipeline. This innovative offering empowers researchers with high quality gRNAs…
Glenmark’s innovative immune-oncology drug for advanced solid tumors and lymphomas receives FDA acceptance for Phase 1/2 clinical study
Glenmark Pharmaceuticals Ltd.’s subsidiary, Glenmark Specialty SA, has achieved a breakthrough in the fight against advanced solid tumors and lymphomas. The US Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for GRC 54276, an…
